



831458 – Trials@Home

Center of Excellence – Remote Decentralised Clinical  
Trials

**WP3 – PILOT**

## D3.6 Midterm recruitment report

**Lead contributor**                    18 Sanofi - Linda Rutgrink  
   2 JCR - Danny van Weelij  
   2 JCR - Katarzyna Lipinska  
   2 JCR - Yvonne van Rijswick  
   1 UMCU - Bart Lagerwaard

**Other contributors**                2 JCR - Maartje Hoffmann  
   14 IDFE - Sabine Dupont

### Document History

<b>Version</b>	<b>Date</b>	<b>Description</b>
V1.0	28 Aug 2024	First version mid-term recruitment report

The Trials@Home project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831458. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

More information can be found on <https://www.imi.europa.eu/>

The research leading to these results was conducted as part of the Trials@Home consortium. This paper only reflects the personal view of the stated authors and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

## Introduction

This report describes the recruitment activities planned and executed, and the resulting recruitment numbers for the RADIAL trial. Although initially this report was planned to describe the recruitment numbers mid-term of the RADIAL trial, due to ongoing discussion on extension of the recruitment period, the consortium decided it would be more informative for this report to describe the recruitment activities on the complete recruitment period from 10 July 2023 to 14 May 2024.

RADIAL was planned to enrol 600 participants in 6 countries, with 150 participants in each site-based arm (Part A conventional and Part A hybrid) and 300 participants in the remote arm (Part B).

Participating countries are presented in [Figure 1](#). Each participating country had multiple conventional sites and 1 remote site. All sites were selected based on pre-determined quality criteria, such as recruitment potential, and access to selected patient population. Additionally, the conventional sites were also selected based on their geographical location and the remote sites were selected based on affinity with remote elements. The location of the remote site in the participating country was not a factor in the selection of the site.

Recruitment was open from 10 July 2023 to 14 May 2024. Although the number of participants planned in the protocol had not been reached, the recruitment period had to be closed to leave enough time for the consortium to conclude and report on the learnings of the RADIAL trial within the Trials@Home project timelines. During the recruitment period of the study, the RADIAL working group 'Recruitment and Retention' meetings were held minimum weekly to monitor recruitment activities.

## Participating countries




Figure 1 Participating countries

## Recruitment activities

The RADIAL protocol described the planned methodologies for Part A and Part B recruitment. A full overview of all applied recruitment activities is available in [Appendix 1](#). Examples of recruitment materials are available in [Appendix 2](#).

### Part A

According to the protocol, potential participants for the conventional and hybrid arms (Part A) were planned to be recruited locally by methods traditionally used in clinical trials. Examples include printed posters and flyers, advertisements in print, on the radio, on television, and recruitment via the site's website or social media pages. Additionally, patients could be recruited through outreach by the investigator to patients in their own clinic's database, to their network of general practitioners, to pharmacies, or to other hospital departments. These methods could make potential participants aware of the study and refer those interested to the study site.

### Part B

According to the protocol, potential participants for the remote arm (Part B) were planned to be recruited using methods approved in the participating countries. These could include countrywide digital advertising on social media (e.g. Facebook, Google, Instagram) and banners on patient advocacy and other relevant websites. In addition, outreach to potentially interested persons in a database and in the investigator's network could be used to raise awareness of the study. All methods used in Part B would direct potential participants to the pre-screener questionnaire on the study website [www.radial.eu](http://www.radial.eu).

This online pre-screener questionnaire was used to assess initial interest and eligibility for the study. When potential participants met the pre-screener eligibility requirements, they were contacted by site personnel for a further eligibility check. Those assessed as being potentially eligible, received access to the full study information and informed consent process, available through an electronic portal.

The website that hosted the pre-screener questionnaire was built by an ecommerce company specialised in the development and conduct of recruitment campaigns through social media. This company developed a messaging framework and personas, which formed the basis for the preparation of website texts and materials for online advertising.

A tailored recruitment strategy, based on the sites experiences, preferences and possibilities was developed for each part B site. Several Part B sites developed and used their own recruitment materials and methods according to their habits and preferences. During the study, when recruitment numbers stayed behind, additional recruitment efforts, including recruitment via social media was initiated in some countries. Recruitment methods used by the remote sites in the different countries are described below. Dates when the recruitment materials were available are listed in [Appendix 1](#).

- In Denmark, the remote site initiated recruitment via emails to 800 patients from the database of an associated diabetes clinic. No online social media campaign was rolled out in Denmark

based on the site's past experiences on the effectiveness of such campaigns. In addition, the site planned to engage their general practitioners' network for referrals, but due to the approaching recruitment deadline and the long contracting timelines, this activity was cancelled.

- In Germany, the remote site used their Site Management Organisation (SMO) network and database to contact potential participants. Furthermore, they contracted a separate recruitment company, who recruit patients via their platform. This company advertises in social media for participation in clinical trials per condition. Potential participants can choose to click and read about a study and are then directed to the site. Additionally, information about the study was posted on a clinical trial recruitment website supported by a Google ads campaign for this.
- In Italy, the consortium-selected ecommerce company developed and managed recruitment campaign. Initially, the campaign planned to include paid advertising on Facebook and Instagram and start in October 2023. However, due to administrative issues (account location vs. activity) and cyber security reasons (credit cards not accepted), Facebook and Instagram did not allow the paid advertising on the RADIAL account, and this was unsolvable within the recruitment period. Alternatively, the prepared materials for Google paid search and Google display advertising were used. The study centre also used their internal database to recruit potential participants.
- In Poland, information about the study was posted on an informative website on human medicines aimed at the public and its Facebook page. Additionally, information about the study was posted on a clinical trial recruitment website supported by a Google ads campaign for this. The study centre additionally used their own patient database to identify and recruit any potential participants.
- In Spain, the site used their network of 21 hospitals to recruit potential participants via primary referrals. The site was also encouraged to advertise the study on their social networks, specifically the site's Instagram profile, but this was not done.
- In the United Kingdom (UK), the remote clinical trial site worked with a local UK recruitment advertising company and developed an online recruitment campaign to target areas with a high population density (Newcastle, Manchester, Birmingham, London). They posted on LinkedIn, Instagram, and Facebook. The site also searched their own database and hospital diabetes department for potentially eligible patients. In addition, the site collaborated with a provider to have them send a mail-out to 2000 patients within the provider's database.

## Supporting activities by the consortium

Within the consortium, several additional activities were developed to enhance recruitment in both Parts A and B. A full overview of recruitment methods and dates when these were available is presented in [Appendix 1](#). Some of the methods are provided in more detail below.

### *International Diabetes Federation Europe (IDFE)*

IDF Europe (IDFE) is the European chapter of the International Diabetes Federation. IDFE is a Trials@Home consortium partner and was involved in the creation of materials and website. IDFE raised awareness of the RADIAL recruitment being open to their members, consisting of .

patients, patient advocates, and health care providers in European countries. From the beginning, IDFE shared RADIAL updates in their member newsletters. News of the recruitment was provided in the IDFE newsletters from October 2023 to March 2024. Two LinkedIn posts (2000 followers) were released when recruitment first opened. RADIAL posts were also featured on IDFE's Instagram account (12 and 20 December 2023). Additionally, IDFE partnered with their local chapters in applicable countries, to post the study on the local associations' websites (Poland and UK). Also, in all countries where the trial was running, local (individual) patient advocates were asked to post about RADIAL in their own social networks.

### *Diabetes Professional Care meeting*

In the UK, most people living with diabetes are treated by general practitioners and specialised nurses. Therefore, the Sponsor presented RADIAL at the Diabetes Professional Care meeting to raise awareness in this group of healthcare professionals.

### *Regular contact with sites*

Sites were engaged by regular contact with or live visits by the Sponsor and/or CRO.

## **Actions taken to improve recruitment**

When recruitment was found to not meet expectations, several additional initiatives were started.

### *Extension of recruitment timelines*

In November 2023, it was decided to prolong recruitment from 6 months to 9 months.

### *Additional sites*

In March 2024, 2 additional Part A sites were opened in the UK.

### *Posts on social media*

Recruitment via social media was started. Country-specific initiatives are described above and in [Appendix 1](#).

### *Protocol Amendment*

In December 2023, a deep-dive by the sponsor. Feedback had been received from several sites that removal of the exclusion criterion of previous Toujeo<sup>®</sup> use and use of fast-/short-action insulins would significantly increase the eligible population. From a medical perspective, it was acceptable to take these 2 criteria out. The amended protocol was approved in March 2024 by the regulators, allowing for subsequent recruitment under the amended criteria.

Main changes to the in- and exclusion criteria:

Allow the inclusion of patients that were already using Toujeo<sup>®</sup>. Allow patients in the study that are on a basal-bolus regimen.

It was also carefully considered whether the exclusion criterion for HbA1C should change from 'below 7.0%' to below '6.5%'. This criterion was found to be an important reason for screen failures. However, it was considered contradictory to medical guidelines in some of the countries to alter this exclusion criterion: the guidelines do not indicate a change in treatment in such cases.

## Recruitment results

The first site was activated on 10 July 2023 and the first participant enrolled on 22 August 2023. The recruitment period, i.e. participants starting the screening period, ended on the 14 May 2024. The last participant was enrolled, i.e. being included in the trial upon eligibility, on 10 June 2024.

For Part A, a total of 174 participants were screened. This resulted in 100 participants in Part A. For part B, 133 interested individuals were pre-screened, of which 15 participants were screened. This resulted in 8 participants enrolled in part B. A major reason for exclusion was the HbA1C criterion.

The weekly recruitment rates for Part A and Part B are presented in [Figure 2](#) and [Figure 3](#), respectively.




Figure 2 Part A recruitment rate per week






Figure 3 Part B recruitment rate per week

Actual enrolment per country is presented in Table 1. Planned and actual enrolment per site is presented in Table 2.

Table 1 Actual recruitment per country

Country	Enrolled in Part A	Enrolled in Part B
Denmark	5	0
Germany	11	4
Italy	14	0
Poland	23	2
Spain	27	0
UK	20	2

Table 2 Planned and actual enrolment per site

Country	Planned	Actual
<b>Denmark</b>	<b>76</b>	<b>5</b>
Site 20803	6	3
Site 20807	5	2
Site 20899 (remote)	65	0
<b>Germany</b>	<b>62</b>	<b>15</b>
Site 27612	15	8
Site 27616	15	3
Site 27699 (remote)	32	4
<b>Italy</b>	<b>74</b>	<b>14</b>
Site 38001	6	5
Site 38002	12	9
Site 38005	7	0
Site 38012	4	0
Site 38099 (remote)	45	0

<b>Country</b>	<b>Planned</b>	<b>Actual</b>
<b>Poland</b>	<b>105</b>	<b>25</b>
Site 61609	10	0
Site 61611	10	0
Site 61613	10	2
Site 61614	10	12
Site 61615	10	1
Site 61616	10	1
Site 61617	10	7
Site 61699 (remote)	35	2
<b>Spain</b>	<b>184</b>	<b>27</b>
Site 72401	20	4
Site 72405	30	2
Site 72407	40	0
Site 72409	12	5
Site 72410	4	4
Site 72412	4	2
Site 72414	8	4
Site 72415	4	6
Site 72417	12	0
Site 72499 (remote)	50	0
<b>UK</b>	<b>106</b>	<b>22</b>
Site 82603	5	2
Site 82604	5	3
Site 82605	5	3
Site 82606	5	5
Site 82610	7	0
Site 82611	7	2
Site 82613	5	4
Site 82614	7	1
Site 82699 (remote)	60	2

## Evaluation

It was planned to enrol approximately 300 participants in Part A and approximately 300 participants in Part B. However, despite several mitigation measures, at the end of the recruitment period, the recruitment numbers were lower than expected: a total of 100 participants were enrolled in Part A and 8 participants in Part B. As recruitment is one of the primary study endpoints, the recruitment numbers will be further evaluated, and results will be described in a future recruitment report.

## Appendices

### Appendix 1

#### List of recruitment activities

Details recruitment activity				Applicable for Part*		Applicable for Country*					
Start date	End date	Category	Description	Part A	Part B	UK	DE	PL	IT	ES	DK
10Apr24	11Apr24	Site Engagement	Sponsor booster visits	x							x
15Nov23	21May24	Database Outreach	Hospital database search	x							x
15Nov23	21May24	Clinic visit recruitment	Discuss study during regular patient visit	x							x
6Nov23	15Apr24	Database Outreach	130 mail-outs to database per week		x						x
15Nov23	15Apr24	Database Outreach	150 letters to database per week		x						x
24Oct23	24Oct23	Site Engagement	Annual meeting Trials@Home		x						x
23Nov23	23Feb24	Online Recruitment Activity	DE recruitment company campaign		x		x				
23Feb24	23Feb24	Site Engagement	Sponsor Visit		x		x				
Early Apr24	30Apr24	Online Recruitment Activity	Clinical trial recruitment website presence		x		x				
4Apr24	4Apr24	Site Engagement Call	Re-training	x					x		
20Feb24	30Apr24	Online Recruitment Activity	Google adds campaign Italy		x				x		
29Nov23	27Mar24	Online Recruitment Activity	10 social media posts Facebook (organic posts)		x				x		
23Feb24	30Apr24	Online Recruitment Activity	10 social media posts Instagram (organic posts)		x				x		
21Feb24	22Feb24	Site Engagement	Sponsor visits	x	x			x			
Early Apr24	30Apr24	Online Recruitment Activity	Banners on informative patient website on medicines		x			x			
Early Apr24	30Apr24	Online Recruitment Activity	Post on Facebook on informative patient website on medicines		x			x			

Details recruitment activity				Applicable for Part*		Applicable for Country*					
Start date	End date	Category	Description	Part A	Part B	UK	DE	PL	IT	ES	DK
Early Apr24	30Apr24	Online Recruitment Activity	Google ads campaign		x			x			
7Dec23	21May24	Online Recruitment Activity	Social media advertising	x		x					
7Dec23	21May24	Network referrals	Network referrals	x		x					
18Sep23	18Sep23	Database outreach	UK database mail-out		x	x					
25Sep23	30Oct24	Online Recruitment Activity	UK social media campaign		x	x					
13Nov23	13Nov23	Site Engagement Call	Recruitment update		x	x					
27Nov23	27Nov23	Site Engagement Call	Recruitment update		x	x					
1Feb24	21May24	Internal Activity	Live support sessions available helpdesk	x		x	x	x	x	x	x
18Dec23	20Dec23	Internal Activity	Brainstorm recruitment enhancement	x	x	x	x	x	x	x	x
20Feb24	21May24	Internal Activity	Protocol amendment UK approved	x	x	x					
5Mar24	21May24	Internal Activity	Protocol amendment EU approved	x	x		x	x	x	x	x
15Nov23	15Nov23	Conference Presence	Presentation Diabetes Professional Care	x	x	x					
23Dec23	23Dec23	Diabetes (patient) Networks	IDFE posts LinkedIn message	x							
15Dec23	15Dec23	Diabetes (patient) Networks	IDFE posts LinkedIn message	x							
7Feb24	7Feb24	Site Engagement Call	Webinar for Investigators	x	x	x	x	x	x	x	x
19Feb24	19Feb24	Conference Presence	Presentation EUCROF	x	x	x	x	x	x	x	x
21Mar24	21Mar24	Site Engagement Call	Workshop eCRF	x	x	x	x	x	x	x	x
15Mar24	15Mar24	Site Engagement Call	Walk-in site session	x	x	x	x	x	x	x	x


Details recruitment activity				Applicable for Part*		Applicable for Country*					
Start date	End date	Category	Description	Part A	Part B	UK	DE	PL	IT	ES	DK
18Apr24	18Apr24	Site Engagement Call	Walk-in site session	x	x	x	x	x	x	x	x
11Dec23	21May24	SMO Agreement	Additional recruitment funds SMO Poland	x				x			
10Oct23	May2024	Site Engagement	Newsletters 1-6	x	x	x	x	x	x	x	x
1Jun23	May2024	Site Engagement	Regular CRO-SMO calls	x	x	x	x	x		x	
Oct2024	May2024	Online Recruitment Activity	Standing RADIAL consortium recruitment meeting	x	x	x	x	x	x	x	x
Jan24	End of study	Patient Engagement	DfP sample pick-up Germany	x	x		x				
Feb24	Feb24	SMO agreement	2 additional sites setup UK	x		x					
Sep22	End of study	Site Engagement	NIHR CRN portfolio inclusion UK	x	x	x					
20Dec23	5Mar24	Internal Activity	Protocol amendment	x	x	x	x	x	x	x	x
Nov23	30Apr24	Diabetes (patient) Networks	Awareness in own social network	x	x		x			x	
9Feb24	30Apr24	Online Recruitment Activity	Google ads campaign		x				x		

\* “X” marks applicability of recruitment activity for Part and for country. For example, ‘UK social media campaign’ is a recruitment activity applicable for part B site in the UK. Multiple answers possible, i.e. some activities are applicable to both parts and multiple countries.

## Appendix 2

### Examples of recruitment materials

Landing page remote participants ([www.radial.eu](http://www.radial.eu))




The screenshot shows the landing page for the RADIAL trial. At the top, there is a navigation bar with the RADIAL logo, an 'Apply Now' button, and several menu items: 'About the RADIAL trial', 'Joining the RADIAL trial', 'About clinical trials', 'Clinical trials in a changing world', and 'FAQs'. Below the navigation bar is a large hero image featuring four diverse people (two older adults and two younger adults) looking at a tablet together. Overlaid on this image is the text: 'Shaping the future of clinical trials'.

Below the hero image, the main text reads: 'The RADIAL trial is testing out whether future clinical trials can be successfully run from participants' homes rather than hospitals or clinics – and the best way to do this. The trial is open to people living with type 2 diabetes who are on long-acting basal insulin.'

There are two columns of text below the main text. The left column is titled 'About RADIAL trial' and 'Why are clinical trials so important?'. The right column is titled 'Clinical trials drive progress in medicine. Today, people are living longer, healthier lives, mainly because others they never met volunteered to take part in clinical trials.'

Below the text columns is an 'About clinical trials' button. At the bottom of the page, there are two more sections. The left section is titled 'Why are we running the RADIAL trial?' and discusses 'Decentralised clinical trials that allow people to take part from home could have significant benefits - but it's important first to carefully study their reliability and participant experience compared with traditional trials run from hospitals and...'. The right section is titled 'How the RADIAL trial will be run' and states 'All RADIAL trial participants will switch from their current long-acting basal insulin to Toujeo®, but half will take part from home using digital technology; if you join via this website, you will be in this group.'




### Fewer visits to the research centres

Clinical trials have always relied on the willingness of participants to make regular visits to a research centre (hospital, medical centre or clinic) for tests and assessments. In some trials, the visits need to be frequent and can be time-consuming. This prospect can deter people from joining or completing a trial, especially if they have to travel. If the journey is difficult or expensive it may also be a barrier to participation for people with limited financial resources. Addressing this barrier, the requirement for regular visits can also impact the flow of participants into the trial.



It is not always possible to change difficult visits to a few visits or enough visits to make a trial feasible. This is an important reason why clinical trials are often difficult to get going and why participants may drop out before the end. The need for participants to attend a research centre has been a barrier to clinical research in a number of studies, all of which have already been published. It is not possible to do a trial if there are no participants.





Paid social Adds

**Paid social ads**

**Persona 1**


Copy 1:

**Headline:**  
For people with type 2 diabetes

**Primary text:**  
The RADIAL trial is open to people with type 2 diabetes who are on long-acting basal insulin

**Description:**  
Take part in a trial at home

**Image Copy:**  
Home-based trial for people with type 2 diabetes  
See if you qualify




Copy 2:  
New suggestion- using diabetes management but excludes improve

**Headline:**  
Managing type 2 diabetes

**Primary text:**  
The trial focuses on diabetes management and offers close, regular medical attention within a structured plan at home

**Description:**  
Learn more about the trial

**Image Copy:**  
Home-based trial for people with type 2 diabetes  
See if you qualify




Copy 3:  
New suggestion- removed diabetes management

**Headline:**  
Managing type 2 diabetes

**Primary text:**  
The RADIAL trial offers close, regular medical attention within a structured plan in a home setting

**Description:**  
Learn more about the trial

**Image Copy:**  
Home-based trial for people with type 2 diabetes  
See if you qualify



Investis/GDPR/PIIData2018

investisdigital. 3

## Organic social adds, Facebook and Instagram


### Facebook Bio Page

RADIAL home-based trial.

[www.Radial.eu](http://www.Radial.eu)

The RADIAL trial is testing whether future clinical trials can be successfully run from participants' homes rather than hospitals or clinics. The trial is suitable for people living with type 2 diabetes and taking long-acting basal insulin.

Medical and health



Investis/GDPR/PIIData2018

investisdigital.

2

### Organic Social - Facebook

#### 1. What is a clinical trial (linking to About Clinical Trials page)

Copy 1:



Clinical research is the 'backbone' of progress in healthcare. The RADIAL trial is seeing if future clinical trials can be run from home. Find out more: [link to page](https://bit.ly/6t8tyle)

Copy 2:

Every single person who joins a clinical trial is making an immensely valuable contribution. The RADIAL trial focuses on people living with type 2 diabetes. Read more: [link to page](https://bit.ly/6t8tyle)

Copy 3:

If you have type 2 diabetes and decide to join the RADIAL trial, your safety and wellbeing will be our top priority. For more information about clinical trials: [link to page](https://bit.ly/6t8tyle)



Investis/GDPR/PIIData2018

investisdigital.

3

## Organic social - Instagram

### 1. What is a clinical trial (linking to About Clinical Trials page)


Copy 1:

Every single person who joins a clinical trial is making an immensely valuable contribution. The RADIAL trial focuses on people living with type 2 diabetes. Link in bio for more information.



Copy 2:

Clinical research like the RADIAL trial cannot happen without people like you. Your needs are at the centre of what we do. Link in bio for more information.




Copy 3:

Our goal is to make clinical trials accessible to everyone who might be eligible. The RADIAL trial is focusing on type 2 diabetes. Link in bio for more information.



Investis/GDPR/PIIData2018

investisdigital. 8



## RADIAL recruitment flyer



### RADIAL is looking for Participants!

Our centre is taking part in the RADIAL trial. The RADIAL trial is testing out whether future clinical trials can be successfully run from participants' homes rather than hospitals or clinics - and the best way to do this.

The trial will last for about 7 months. The first weeks will be the screening phase where the research team will make certain the trial is suitable for you.

If the study is suitable for you and you are willing to continue, you will be randomly assigned to either the traditional or hybrid arm for the treatment period.

#### Traditional approach



Assessments are carried out during visits to a research centre (hospital or clinic).

#### Hybrid approach



Some visits to the research centre are involved, but several assessments are carried out via technology from the participant's home.

During this treatment, you will start injecting Toujeo®/ Insulin Glargine 300 U/mL instead of your current basal insulin, measure your glucose levels frequently and enter study data in the provided study application via your smartphone or tablet.

The RADIAL trial is suitable for people aged 18+ who have lived with type 2 diabetes for at least a year and have been receiving a stable dose of long-acting basal insulin for at least 3 months.

Participants should not have achieved optimal glucose management on their current long-acting basal insulin; their HbA1c (a measure of average blood glucose over time) should be over 7 (but no higher than 10). Participants should not be using mealtime or mixed insulins.

These are the main requirements for joining the trial. However, the study team will need to carry out a full medical assessment for each person who is interested in joining to confirm the trial is suitable for them.

### Would you like to know more?


(site contact details)

## News articles on Diabetes Association websites

22 668 47 19 sekretariat@diabetyk.org.pl

**POLSKIE STOWARZYSZENIE DIABETYKÓW**


START AKTUALNOŚCI O STOWARZYSZENIU O CUKRZYCY KONTAKT ENGLISH 1,5% PODATKU



### Przypominamy – trwa nabór do badania klinicznego RADIAL

10.04.2024

Polskie Stowarzyszenie Diabetyków bierze udział w badaniu klinicznym RADIAL dla osób dorosłych z cukrzycą typu 2 rozpoznaną od co najmniej roku, które stosują insulinę bazalną (zwaną również insuliną długodziałającą). Celem badania RADIAL jest przetestowanie...



### Nowoczesne podejście do badań klinicznych

08.02.2024

Polskie Stowarzyszenie Diabetyków bierze udział w badaniu klinicznym RADIAL dla osób dorosłych z cukrzycą typu 2 rozpoznaną od co najmniej roku, które stosują insulinę bazalną (zwaną również insuliną długodziałającą). Celem badania RADIAL jest przetestowanie...

#### Najnowsze wiadomości

- Webinar edukacyjny organizowany przez firmę Abbott – psychoedukacja w cukrzycy
- Kompas w telefonie mierzy poziom glukozy
- Opieka farmaceutyczna nad pacjentem z cukrzycą typu 2. Farmaceuta nieocenionym i niedocenionym wsparciem pacjenta
- Webinar pt. "Ostrą igiełką czy tęym harpunem – czyli dlaczego tak wiele zależy od niepozornej igły?"
- Ruszamy się!
- 30-lecie Waleckiego Kola Diabetyków
- Bez nadmiaru cukru i soli... czyli jak się odżywiać przy cukrzycowej chorobie nerek
- XXXIII Pielgrzymka Diabetyków na Jasną Górę
- Insulinooporność jedną z głównych

TALK TO US ABOUT DIABETES

**DiABETES UK**  
KNOW DIABETES. FIGHT DIABETES.

0345 123 2399 [Donate](#)

[News and Views](#) [Forum](#) [Membership](#) [Professionals](#) [Shop](#) [Learning Zone](#) [Diabetes and Me](#)

[Preventing Type 2](#) [Diabetes: the basics](#) [Living with diabetes](#) [Our research](#) [How we help](#) [Get involved](#)

[Home](#) > [Our research](#) > [Get involved](#) > [Take part in research](#) > [Trial at home](#) [Save for later](#)

# TAKE PART IN INSULIN TRIAL FOR TYPE 2 AT HOME

 **December 2023- May 2024**

 **UK wide** | University Medical Center Utrecht

**Pan-European proof-of-concept study comparing Decentralised Clinical Trial (DCT) and hybrid approaches to conventional clinical trial approaches in patients with Type 2 diabetes mellitus treated with Toujeo**

Researchers at University Medical Center Utrecht (on behalf of EU/EFPIA Innovative Medicines Initiative Joint Undertaking Trials@Home) would like to recruit people aged over 18 with type 2 diabetes, who are treated with insulin already but not optimally controlled, to take part in a clinical trial testing a long-acting basal insulin (Toujeo®). They hope to find out if people can participate in this trial at their own homes, with researchers at Newcastle Trust following their treatment remotely.

If you are living anywhere in the UK, you can participate to this home-based trial. You'll be involved in a 24-week treatment with (Toujeo®). Study medication, the glucometer, test strips and other materials will be delivered. You'll be followed remotely via video contacts.

For more information please visit the [website](#).

**Find your next favourite meal**

We've got loads of recipes to choose from. All our recipes have been checked and approved by a specialist team of dietitians, so you'll always know what's in your

[Try some of these now](#)